Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
204.82
+0.62 (+0.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims
September 22, 2023
California Attorney General Rob Bonta has taken legal action against two anti-abortion organizations, Heartbeat International (HBI) and RealOptions Obria, for making unsupported claims about reversing...
Via
Benzinga
(BIIB) - Analyzing Biogen's Short Interest
September 20, 2023
Via
Benzinga
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
September 15, 2023
Via
Benzinga
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
September 09, 2023
Buying a biotech is a good move, but it might not be enough to entice investors.
Via
The Motley Fool
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
September 07, 2023
Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners.
Via
InvestorPlace
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
September 06, 2023
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a
Via
Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
September 04, 2023
Via
Benzinga
(BIIB) - Analyzing Biogen's Short Interest
September 01, 2023
Via
Benzinga
Analyst Ratings for Biogen
August 29, 2023
Via
Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
September 06, 2023
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...
Via
Benzinga
Better Buy: Biogen vs. Eli Lilly
August 29, 2023
This battle of biotech giants has a clear winner.
Via
The Motley Fool
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today
August 14, 2023
Via
Benzinga
The 3 Best Biotech Stocks to Buy Now: September 2023
September 04, 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.
Via
InvestorPlace
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment
August 31, 2023
The company is now focusing on its launch in postpartum depression.
Via
Investor's Business Daily
The 7 Most Promising Momentum Stocks to Own Now
August 31, 2023
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.
Via
InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
August 30, 2023
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.
Via
InvestorPlace
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
August 28, 2023
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.
Via
The Motley Fool
Looking Into Biogen's Recent Short Interest
August 08, 2023
Via
Benzinga
Is Sage Therapeutics a Contrarian Buy?
August 08, 2023
A regulatory setback weighed heavily on the drugmaker's shares Monday.
Via
The Motley Fool
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
August 24, 2023
Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5%
Via
InvestorPlace
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
August 24, 2023
The pharmaceutical company's growth prospects have taken a big hit.
Via
The Motley Fool
Why Shares of Sage Therapeutics Slumped This Week
August 11, 2023
The company got bad news from the FDA and saw increased losses.
Via
The Motley Fool
Exposures
Product Safety
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
August 10, 2023
The company's rare disease portfolio may soon get an upgrade.
Via
The Motley Fool
With an Acquisition on the Way, Is Biogen Stock a Buy?
August 09, 2023
Can the biotech finally get back in the good graces of investors?
Via
The Motley Fool
Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?
August 09, 2023
Lilly shares surged 15% in one day to a record high. Here's what you should know.
Via
Investor's Business Daily
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
August 08, 2023
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market...
Via
Benzinga
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
August 07, 2023
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter
Via
Benzinga
Dow Rises Over 300 Points To Start The Week
August 07, 2023
The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.